Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Allen

Showing results (891-900 of 1,089) with videos related to

Pageof 109
Sort By:
Biomarker Research|June 6, 2021
The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinomaChi T Viet, Gary Yu, Kesava Asam, et al.
Science (New York, N.Y.)|June 23, 2018
Assessment of methane emissions from the U.S. oil and gas supply chainRamón A Alvarez, Daniel Zavala-Araiza, David R Lyon, et al.
Advanced Biology|August 4, 2022
Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral CancerColeen Doan, Bradley E Aouizerat, Yi Ye, et al.
Nature Medicine|February 11, 2004
HIV evolution: CTL escape mutation and reversion after transmissionA J Leslie, K J Pfafferott, P Chetty, et al.
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|March 19, 2026
Acute thoracolumbar burst fractures (AO types A3/A4) with and without concomitant posterior ligamentous complex injury: treatment outcomes in surgically and nonsurgically managed patients. A multi-center prospective studyJose A Canseco, Maximilian Reinhold, Jonathan Dalton, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2007
Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformationsW N Washburn, T W Harper, G Wu, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2001
BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptorA V Gavai, P M Sher, A B Mikkilineni, et al.
Cell Reports|July 18, 2023
SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neckNupur Nigam, Benjamin Bernard, Samantha Sevilla, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
BMS-201620: a selective beta 3 agonistW N Washburn, C-Q Sun, G Bisacchi, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2001
Beta 3 agonists. Part 1: evolution from inception to BMS-194449W N Washburn, P M Sher, K M Poss, et al.
Pageof 109

Showing results (891-900 of 1,089) with videos related to

Sort By:
Pageof 109
Biomarker Research|June 6, 2021
The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinomaChi T Viet, Gary Yu, Kesava Asam, et al.
Science (New York, N.Y.)|June 23, 2018
Assessment of methane emissions from the U.S. oil and gas supply chainRamón A Alvarez, Daniel Zavala-Araiza, David R Lyon, et al.
Advanced Biology|August 4, 2022
Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral CancerColeen Doan, Bradley E Aouizerat, Yi Ye, et al.
Nature Medicine|February 11, 2004
HIV evolution: CTL escape mutation and reversion after transmissionA J Leslie, K J Pfafferott, P Chetty, et al.
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|March 19, 2026
Acute thoracolumbar burst fractures (AO types A3/A4) with and without concomitant posterior ligamentous complex injury: treatment outcomes in surgically and nonsurgically managed patients. A multi-center prospective studyJose A Canseco, Maximilian Reinhold, Jonathan Dalton, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2007
Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformationsW N Washburn, T W Harper, G Wu, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2001
BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptorA V Gavai, P M Sher, A B Mikkilineni, et al.
Cell Reports|July 18, 2023
SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neckNupur Nigam, Benjamin Bernard, Samantha Sevilla, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
BMS-201620: a selective beta 3 agonistW N Washburn, C-Q Sun, G Bisacchi, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2001
Beta 3 agonists. Part 1: evolution from inception to BMS-194449W N Washburn, P M Sher, K M Poss, et al.
Pageof 109